Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer

Pancreatic Adenocarcinoma Clinical Trial

— CAPANCOVID-19  

Official title:

Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04406571
• Other study ID #: PO20042
• Status: Completed
• Start date: April 1, 2020
• Est. completion date: May 31, 2022

Study information

• Verified date: January 2024
• Source: CHU de Reims
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Pancreatic adenocarcinoma will be the 2nd cause of death by cancer in Europe in 2030. Pancreatic adenocarcinoma has poor prognosis with an all-stages combined 5-year survival rate below 8%.

Since December 2019, a new coronavirus (Severe Acute Respiratory Syndrome Corona Virus 2, SARS-CoV-2) is responsible of COVID-19 infection with potentially severe respiratory syndrome or even multi-organ failure. An increased risk of severe COVID-19 infection in cancer patients is suggested in several Chinese series. Cancer care structures quickly reorganized to limit high-risk situations (diagnostic procedure, major surgery, cytotoxic poly-chemotherapy) and use alternatives such as on-hold chemotherapy. These reorganizations could be associated with a loss of chance for pancreatic adenocarcinoma.

Description:

The aim of this study is to study impact of reorganization of the healthcare system during COVID-19 pandemic on pancreatic adenocarcinoma patients management

Recruitment information / eligibility

• Status: Completed
• Enrollment: 700
• Est. completion date: May 31, 2022
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria :

1. aged 18 or over,

2. with pancreatic adenocarcinoma diagnosed by anatomopathological specimen or without biopsy but with suspicion of pancreatic adenocarcinoma in presence of imaging techniques or Ca19.9 level without evidence for neuroendocrine tumor,

3. assessed during multidisciplinary meeting in one participating center between 01/09/2019 and 31/10/2020,

4. accepting to participate to the study,

5. with or without SARS-CoV-2 infection.

Exclusion criteria :

1. with neuroendocrine neoplasia

2. for whom histology showed non pancreatic

3. with cystadenoma or IPMN without invasive adenocarcinoma

Related Conditions & MeSH terms

• Adenocarcinoma
• COVID-19
• Pancreatic Adenocarcinoma

Intervention

Other:
• Data record
Data record

Locations

Country	Name	City	State
France	Damien JOLLY	Reims

Sponsors (1)

Lead Sponsor	Collaborator
CHU de Reims

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pancreatic adenocarcinoma treatment	curative surgery (with or without chemotherapy), chemotherapy only or exclusive supportive care	6 months